Daily Newsletter

22 August 2023

Daily Newsletter

22 August 2023

Leo Pharma to acquire US company Timber Pharmaceuticals

The company will bolster its medical dermatology pipeline by gaining rights to Timber’s TMB-001.

Vishnu Priyan August 22 2023

Leo Pharma has entered an agreement for the acquisition of US-based clinical-stage biopharma firm Timber Pharmaceuticals for $36m. 

Timber develops and markets therapies to treat rare and orphan dermatologic conditions.

The deal comprises an initial upfront payment of $14m followed by $22m in contingent value rights on meeting specified future milestones.

Leo will bolster its medical dermatology pipeline by gaining rights to a late-stage investigational product candidate of Timber, TMB-001. 

TMB-001 is a new formulation of the active ingredient isotretinoin for topical use. It is intended for the treatment of congenital ichthyosis, a rare skin condition.

The US Food and Drug Administration (FDA) previously granted orphan and breakthrough designations for the asset. A decision on approval is anticipated in 2025. 

TMB-001 demonstrated positive results in a Phase II clinical trial. Recruitment for a Phase III study is underway in Europe and the US.

Leo Pharma CEO Christophe Bourdon stated: “Signing an agreement to acquire Timber Pharmaceuticals and TMB-001, which is still subject to certain closing conditions, is an additional step in delivering on our strategy. 

“We will add an attractive late-stage asset to our medical dermatology pipeline and strengthen our team in the US. 

“And most importantly, we will add an asset with a promising outlook to be able to help patients suffering from a debilitating disease who today have no proper treatment options.”

The deal will be concluded in the fourth quarter of 2023.

Multiple Myeloma (MM) pipeline is dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close